#USA #New York #Rosen Law Firm #Securities Class Action #Immutep Ltd.

Rosen Law Firm Investigates Immutep Ltd.

On March 18, 2026, the Rosen Law Firm, a well-known global leader in investor rights, announced it is probing potential securities fraud claims arising from alleged misleading information provided by Immutep Ltd. This investigation comes in light of alarming news that could significantly impact shareholders of the company listed under NASDAQ symbol IMMP.

The Allegations

Rosen Law Firm’s investigation was sparked by a recent press release from Immutep issued on March 13, 2026, which revealed critical information regarding the status of their Phase III clinical trial, TACTI-004. The Independent Data Monitoring Committee (IDMC), responsible for overseeing the integrity of the trial, recommended its discontinuation following a routine interim analysis that indicated a lack of efficacy. This decision raised serious concerns regarding the reliability of the information previously provided to investors, suggesting Immutep may have misled the public about its product.

Upon this announcement, there was a dramatic drop in Immutep's American Depositary Receipt (ADR) price, plummeting by 82.6%, which translates to a loss of $2.28 per share, closing the day at $0.48. Such a sharp decline could qualify investors for potential compensation under class action claims, allowing them to seek recovery for their monetary losses without incurring upfront legal fees due to contingency arrangements.

How to Participate in the Class Action

Investors who acquired Immutep securities and wish to pursue claims are encouraged to reach out to the Rosen Law Firm. Interested parties can find more information or express their intent to join the class action by visiting the firm's website or by contacting Phillip Kim, Esq. directly by phone or email. The firm emphasizes that no out-of-pocket costs are incurred by participants as legal fees will only be taken from any recovery achieved.

About Rosen Law Firm

The Rosen Law Firm has a remarkable reputation, having been involved in some of the largest securities class action settlements in history. With a track record of ensuring justice for investors, the firm has distinguished itself by obtaining high-value settlements, including over $438 million for investors in 2019 alone. Their commitment to investor rights has positioned them as a leading voice in securities class action litigation, providing rigorous representation while navigating highly complex legal proceedings.

Law firm founder Laurence Rosen has been acknowledged among industry leaders, being named a ‘Titan of the Plaintiff’s Bar’ by Law360. The firm’s legal team has garnered acclaim from recognized platforms like Lawdragon and Super Lawyers, making it a principled choice for affected shareholders.

Active communication is crucial during such investigations, and Rosen Law Firm has encouraged stakeholders to stay updated via their LinkedIn, Twitter, and Facebook platforms. They emphasize the importance of selecting legal counsel with substantial experience, as often many firms lack the necessary expertise and resources to lead securities class action cases successfully.

Conclusion

In conclusion, the ongoing investigation into Immutep Ltd. signals potential for claims that could allow investors to reclaim losses from misleading information disseminated by the company. As the situation unfolds, it will be vital for affected shareholders to remain engaged with developments and take appropriate action to protect their interests.